StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$21.89−0.22 (-1.00%)

Close on Nov 18, 2026Market cap $3.69BP/E –Yield –

Tango Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Tango Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$136.35M. For fiscal 2025 it was -$111.29M. The highest annual figure on record is -$52.20M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$111.29M–
FY2024Dec 31, 2024-$145.60M–
FY2023Dec 31, 2023-$114.17M–
FY2022Dec 31, 2022-$111.07M–
FY2021Dec 31, 2021-$58.19M–
FY2020Dec 31, 2020-$52.20M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$59.79M–
Q1 FY2026Mar 31, 2026-$48.77M–
Q4 FY2025Dec 31, 2025-$41.86M–
Q3 FY2025Sep 30, 2025$14.07M–
Q2 FY2025Jun 30, 2025-$40.97M–
Q1 FY2025Mar 31, 2025-$42.53M–
Q4 FY2024Dec 31, 2024-$40.91M–
Q3 FY2024Sep 30, 2024-$32.88M–
Q2 FY2024Jun 30, 2024-$29.55M–
Q1 FY2024Mar 31, 2024-$42.26M–
Q4 FY2023Dec 31, 2023-$35.01M–
Q3 FY2023Sep 30, 2023-$25.63M–
Q2 FY2023Jun 30, 2023-$23.25M–
Q1 FY2023Mar 31, 2023-$30.29M–
Q4 FY2022Dec 31, 2022-$30.57M–
Q3 FY2022Sep 30, 2022-$29.92M–
Q2 FY2022Jun 30, 2022-$25.20M–
Q1 FY2022Mar 31, 2022-$25.38M–
Q4 FY2021Dec 31, 2021-$21.98M–
Q3 FY2021Sep 30, 2021-$19.57M–
Q2 FY2021Jun 30, 2021-$4.56M–
Q1 FY2021Mar 31, 2021-$12.08M–
Q4 FY2020Dec 31, 2020-$8.94M–
Q3 FY2020Sep 30, 2020-$26.76M–

More Tango Therapeutics figures

See a number that looks wrong?